Vigil Neuroscience
Latest round
- Series B
Last raised
- Aug 2021
Total raised
- $120M
Investors
- 14
About Vigil Neuroscience
a. Vigil Neuro develops microglia-based therapies for the treatment of neurodegenerative diseases. In August 2021, Vigil Neuroscience, Inc. As of November 2021, Vigil Neuroscience, Inc. Ivana Magovcevic-Liebisch is President and CEO of the company. Vigil Neuroscience, Inc. develops VGL101, a fully human monoclonal antibody, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), which is a microglia sensor that mediates responses to environmental signals to maintain brain homeostasis. Vigil Neuroscience, Inc.
Who invested in Vigil Neuroscience
14 investors across 2 rounds
See all investors in Vigil Neuroscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Vigil Neuroscience
Who invested in Vigil Neuroscience?
Vigil Neuroscience has 14 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vigil Neuroscience raised?
Vigil Neuroscience has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Vigil Neuroscience last raise money?
Vigil Neuroscience's most recent round on record is a Series B, in Aug 2021.
What does Vigil Neuroscience do?
Vigil Neuroscience is a biotechnology company.
Where is Vigil Neuroscience headquartered?
Vigil Neuroscience is headquartered in Watertown, US.
Which VCs invest in companies like Vigil Neuroscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Vigil Neuroscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Vigil Neuroscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.